IDO1 and post-traumatic stress disorder: Cilostazol reportedly prevented the development of anxiety symptoms and post-traumatic stress disorder (PTSD)-induced increases in hippocampal IDO and IL-1β, improving neuroinflammation, and has been proposed as a promising candidate for further PTSD pharmacotherapeutic research (Sadeghi et al., 2024).